Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Эндокринологические осложнения на фоне противоопухолевой терапии. Лекция для практических врачей
Эндокринологические осложнения на фоне противоопухолевой терапии. Лекция для практических врачей
Глибка А.А., Мазурина Н.В., Трошина Е.А. Эндокринологические осложнения на фоне противоопухолевой терапии. Лекция для практических врачей. Consilium Medicum. 2022;24(6):416–421.
DOI: 10.26442/20751753.2022.6.201695
DOI: 10.26442/20751753.2022.6.201695
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Таргетная терапия и ингибиторы контрольных точек иммунного ответа (ИКТИО) все чаще используются для лечения многих солидных опухолей. Применение алпелисиба и ИКТИО сопряжено с риском развития различных побочных эффектов, в частности эндокринных дисфункций. В этой лекции четко прописаны первичный скрининг, мониторинг, подбор терапии и неотложные ситуации для каждой эндокринопатии, т.е. для гипергликемии во время лечения алпелисибом и для деструктивного тиреоидита и гипофизита на фоне терапии ИКТИО.
Ключевые слова: гипергликемия, деструктивный тиреоидит, гипофизит, алпелисиб, ингибиторы контрольных точек иммунного ответа
Keywords: hyperglycemia, destructive thyroiditis, hypophysitis, alpelisib, immune checkpoint inhibitors
Ключевые слова: гипергликемия, деструктивный тиреоидит, гипофизит, алпелисиб, ингибиторы контрольных точек иммунного ответа
________________________________________________
Keywords: hyperglycemia, destructive thyroiditis, hypophysitis, alpelisib, immune checkpoint inhibitors
Полный текст
Список литературы
1. Kosák M. Endocrine late effects of cancer treatment. Klin Onkol. 2021;34(6):440-9. DOI:10.48095/ccko2021440
2. Bekema HJ, MacLennan S, Imamura M, et al. Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. Eur Urol. 2013;64(5):799-810. DOI:10.1016/j.eururo.2013.04.033
3. Darzy KH, Shalet SM. Hypopituitarism following radiotherapy. Pituitary. 2009;12(1):40-50. DOI:10.1007/s11102-008-0088-4
4. van Dorp W, van Beek RD, Laven JS, et al. Long-term endocrine side effects of childhood Hodgkin's lymphoma treatment: a review. Hum Reprod Update. 2012;18(1):12-28. DOI:10.1093/humupd/dmr038
5. Боброва Е.И., Фадеев В.В., Сотников В.М., и др. Морфофункциональные нарушения щитовидной железы после лучевой терапии опухолевых заболеваний. Клиническая и экспериментальная тиреоидология. 2014;10(3):45-52 [Bobrova EI, Fadeyev VV, Sotnikov VM, et al. Thyroid disorders after radiation therapy in childhood. Clinical and experimental thyroidology. 2014;10(3):45-52 (in Russian)]. DOI:10.14341/ket2014345-52
6. Рак молочной железы. ВОЗ. 2021. Режим доступа: https://www.who.int/ru/news-room/fact-sheets/detail/breast-cancer. Ссылка активна на 23.05.2022 [Mammary cancer. WHO. 2021. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/breast-cancer. Accessed: 23.05.2022 (in Russian)].
7. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):33. DOI:10.1186/s40659-017-0140-9
8. Cancer deaths by type, World, 2019. Total annual number of deaths from cancers across all ages and both sexes, broken down by cancer type. Our World in Data. Available at: https://ourworldindata.org/grapher/total-cancer-deaths-by-type?time=earliest. Accessed: 23.05.2022.
9. Tsang JYS, Tse GM. Molecular Classification of Breast Cancer. Adv Anat Pathol. 2020;27(1):27-35. DOI:10.1097/PAP.0000000000000232
10. Стенина М.Б., Жукова Л.Г., Королева И.А., и др. Практические рекомендации по лекарственному лечению рака молочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2020;10:09 [Stenina MB, Zhukova LG, Koroleva IA, et al. Prakticheskie rekomendatsii po lekarstvennomu lecheniiu raka molochnoi zhelezy. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO #3s2. 2020;10:09 (in Russian)]. DOI:10.18027 / 2224-5057-2019-9-3s2-128-163
11. Семиглазова Т.Ю., Семиглазов В.В., Клименко В.В., и др. Применение алпелисиба для лечения HR+ HER2-метастатического рака молочной железы у пациентов с мутацией PIK3CA: результаты исследования SOLAR-1. Фарматека. 2020;7:15-23 [Semiglazova TIu, Semiglazov VV, Klimenko VV, et al. Primenenie alpelisiba dlia lecheniia HR HER2-metastaticheskogo raka molochnoi zhelezy u patsientov s mutatsiei PIK3CA: rezul'taty issledovaniia SOLAR-1. Farmateka. 2020;7:15-23 (in Russian)]. DOI:10.18565/pharmateca.2020.7.15-23
12. Chen X, Wei L, Chi L, et al. Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database. Br J Clin Pharmacol. 2022;88(5):2180-9. DOI:10.1111/bcp.15143
13. Мазурина Н.В., Артамонова Е.В., Белоярцева М.Ф., и др. Консенсус по профилактике и коррекции гипергликемии у пациентов, получающих терапию препаратом алпелисиб. Современная Онкология. 2020;22(4):56-9 [Mazurina NV, Artamonova EV, Beloyartseva MF, et al. The consensus on the prevention and correction of hyperglyce-mia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib. Journal of Modern Oncology. 2020;22(4):56-9 (in Russian)]. DOI:10.26442/18151434.2020.4.200566
14. Inaba H, Ariyasu H, Okuhira H, et al. Endocrine dysfunctions during treatment of immune-checkpoint inhibitors. Trends Immunother. 2018;2(2):565. DOI:10.24294/ti.v2i2.606
15. Шубникова Е.В., Букатина Т.М., Вельц Н.Ю., и др. Ингибиторы контрольных точек иммунного ответа: новые риски нового класса противоопухолевых средств. Безопасность и риск фармакотерапии. 2020;8(1):9-22 [Shubnikova EV, Bukatina TM, Velts NYu, et al. Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents. Safety and Risk of Pharmacotherapy. 2020;8(1):9-22 (in Russian)]. DOI:10.30895/2312-7821-2020-8-1-9-22
16. Ferrari SM, Fallahi P, Galetta F, et al. Thyroid disorders induced by checkpoint inhibitors. Rev Endocr Metab Disord. 2018;19(4):325-33. DOI:10.1007/s11154-018-9463-2
17. Государственный реестр лекарственных средств. Режим доступа: https://grls.rosminzdrav.ru/grls.aspx. Ссылка активна на 22.05.2022 [Available at: https://grls.rosminzdrav.ru/grls.aspx. Accessed: 22.05.2022 (in Russian)].
18. Tjulandin S, Demidov L, Moiseyenko V, et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. Eur J Cancer. 2021;149:222-32. DOI:10.1016/j.ejca.2021.02.030
19. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173-82. DOI:10.1001/jamaoncol.2017.3064
20. Chang LS, Barroso-Sousa R, Tolaney SM, et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019;40(1):17-65. DOI:10.1210/er.2018-00006
21. Kurimoto C, Inaba H, Ariyasu H, et al. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer Sci. 2020;111(5):1468-77. DOI:10.1111/cas.14363
22. Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583-9. DOI:10.1093/annonc/mdw640
23. Yamauchi I, Yasoda A, Matsumoto S, et al. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS One. 2019;14(5):e0216954. DOI:10.1371/journal.pone.0216954
24. Higham CE, Olsson-Brown A, Carroll P, et al. SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect. 2018;7(7):G1-7. DOI:10.1530/EC-18-0068
25. Castinetti F, Borson-Chazot F. Immunotherapy-induced endocrinopathies: Insights from the 2018 French Endocrine Society Guidelines. Bull Cancer. 2019;106(5):492-6. DOI:10.1016/j.bulcan.2019.02.003
26. Трошина Е.А., Панфилова Е.А., Михина М.С., и др. Клинические рекомендации «Острые и хронические тиреоидиты (исключая аутоиммунный тиреоидит)». Проблемы эндокринологии. 2021;67(2):57-83 [Troshina EA, Panfilova EA, Mikhina MS, et al. Clinical practice guidelines for acute and chronic thyroiditis (excluding autoimmune thyroiditis). Problemy Endokrinologii. 2021;67(2):57-83 (in Russian)]. DOI:10.14341/probl12747
27. Garon-Czmil J, Petitpain N, Rouby F, et al. Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database. Sci Rep. 2019;9(1):19419. DOI:10.1038/s41598-019-56026-5
28. Gutenberg A, Larsen J, Lupi I, et al. A radiologic score to distinguish autoimmune hypophysitis from nonsecreting pituitary adenoma preoperatively. AJNR Am J Neuroradiol. 2009;30(9):1766-72. DOI:10.3174/ajnr.A1714
29. Клинические рекомендации. Первичная надпочечниковая недостаточность, 2021 г. Режим доступа: https://cr.minzdrav.gov.ru/recomend/524_2/ Ссылка активна на 23.05.2022 [Klinicheskie rekomendatsii. Pervichnaia nadpochechnikovaia nedostatochnost', 2021 g. Available at https://cr.minzdrav.gov.ru/recomend/524_2/ Accessed: 23.05.2022 (in Russian)].
30. Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124(18):3706-14. DOI:10.1002/cncr.31629
31. Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99:4078-85. DOI:10.1210/jc.2014-2306
32. Проценко С. А., Антимоник Н. Ю., Берштейн Л. М., и др. Практические рекомендации по управлению иммуноопосредованными нежелательными явлениями. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2020;10:50 [Protsenko SA, Antimonik N Iu, Bershtein LM, et al. Prakticheskie rekomendatsii po upravleniiu immunooposredovannymi nezhelatel'nymi iavleniiami. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO #3s2. 2020;10:50 (in Russian)].
DOI:10.18027 / 2224-5057-2020-10-3s2-50
2. Bekema HJ, MacLennan S, Imamura M, et al. Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. Eur Urol. 2013;64(5):799-810. DOI:10.1016/j.eururo.2013.04.033
3. Darzy KH, Shalet SM. Hypopituitarism following radiotherapy. Pituitary. 2009;12(1):40-50. DOI:10.1007/s11102-008-0088-4
4. van Dorp W, van Beek RD, Laven JS, et al. Long-term endocrine side effects of childhood Hodgkin's lymphoma treatment: a review. Hum Reprod Update. 2012;18(1):12-28. DOI:10.1093/humupd/dmr038
5. Bobrova EI, Fadeyev VV, Sotnikov VM, et al. Thyroid disorders after radiation therapy in childhood. Clinical and experimental thyroidology. 2014;10(3):45-52 (in Russian). DOI:10.14341/ket2014345-52
6. Рак молочной железы. ВОЗ. 2021. Режим доступа: https://www.who.int/ru/news-room/fact-sheets/detail/breast-cancer. Ссылка активна на 23.05.2022 [Mammary cancer. WHO. 2021. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/breast-cancer. Accessed: 23.05.2022 (in Russian)].
7. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):33. DOI:10.1186/s40659-017-0140-9
8. Cancer deaths by type, World, 2019. Total annual number of deaths from cancers across all ages and both sexes, broken down by cancer type. Our World in Data. Available at: https://ourworldindata.org/grapher/total-cancer-deaths-by-type?time=earliest. Accessed: 23.05.2022.
9. Tsang JYS, Tse GM. Molecular Classification of Breast Cancer. Adv Anat Pathol. 2020;27(1):27-35. DOI:10.1097/PAP.0000000000000232
10. Stenina MB, Zhukova LG, Koroleva IA, et al. Prakticheskie rekomendatsii po lekarstvennomu lecheniiu raka molochnoi zhelezy. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO #3s2. 2020;10:09 (in Russian). DOI:10.18027 / 2224-5057-2019-9-3s2-128-163
11. Semiglazova TIu, Semiglazov VV, Klimenko VV, et al. Primenenie alpelisiba dlia lecheniia HR HER2-metastaticheskogo raka molochnoi zhelezy u patsientov s mutatsiei PIK3CA: rezul'taty issledovaniia SOLAR-1. Farmateka. 2020;7:15-23 (in Russian). DOI:10.18565/pharmateca.2020.7.15-23
12. Chen X, Wei L, Chi L, et al. Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database. Br J Clin Pharmacol. 2022;88(5):2180-9. DOI:10.1111/bcp.15143
13. Mazurina NV, Artamonova EV, Beloyartseva MF, et al. The consensus on the prevention and correction of hyperglyce-mia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib. Journal of Modern Oncology. 2020;22(4):56-9 (in Russian). DOI:10.26442/18151434.2020.4.200566
14. Inaba H, Ariyasu H, Okuhira H, et al. Endocrine dysfunctions during treatment of immune-checkpoint inhibitors. Trends Immunother. 2018;2(2):565. DOI:10.24294/ti.v2i2.606
15. Shubnikova EV, Bukatina TM, Velts NYu, et al. Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents. Safety and Risk of Pharmacotherapy. 2020;8(1):9-22 (in Russian). DOI:10.30895/2312-7821-2020-8-1-9-22
16. Ferrari SM, Fallahi P, Galetta F, et al. Thyroid disorders induced by checkpoint inhibitors. Rev Endocr Metab Disord. 2018;19(4):325-33. DOI:10.1007/s11154-018-9463-2
17. Available at: https://grls.rosminzdrav.ru/grls.aspx. Accessed: 22.05.2022 (in Russian).
18. Tjulandin S, Demidov L, Moiseyenko V, et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. Eur J Cancer. 2021;149:222-32. DOI:10.1016/j.ejca.2021.02.030
19. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173-82. DOI:10.1001/jamaoncol.2017.3064
20. Chang LS, Barroso-Sousa R, Tolaney SM, et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019;40(1):17-65. DOI:10.1210/er.2018-00006
21. Kurimoto C, Inaba H, Ariyasu H, et al. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer Sci. 2020;111(5):1468-77. DOI:10.1111/cas.14363
22. Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583-9. DOI:10.1093/annonc/mdw640
23. Yamauchi I, Yasoda A, Matsumoto S, et al. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS One. 2019;14(5):e0216954. DOI:10.1371/journal.pone.0216954
24. Higham CE, Olsson-Brown A, Carroll P, et al. SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect. 2018;7(7):G1-7. DOI:10.1530/EC-18-0068
25. Castinetti F, Borson-Chazot F. Immunotherapy-induced endocrinopathies: Insights from the 2018 French Endocrine Society Guidelines. Bull Cancer. 2019;106(5):492-6. DOI:10.1016/j.bulcan.2019.02.003
26. Troshina EA, Panfilova EA, Mikhina MS, et al. Clinical practice guidelines for acute and chronic thyroiditis (excluding autoimmune thyroiditis). Problemy Endokrinologii. 2021;67(2):57-83 (in Russian). DOI:10.14341/probl12747
27. Garon-Czmil J, Petitpain N, Rouby F, et al. Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database. Sci Rep. 2019;9(1):19419. DOI:10.1038/s41598-019-56026-5
28. Gutenberg A, Larsen J, Lupi I, et al. A radiologic score to distinguish autoimmune hypophysitis from nonsecreting pituitary adenoma preoperatively. AJNR Am J Neuroradiol. 2009;30(9):1766-72. DOI:10.3174/ajnr.A1714
29. Klinicheskie rekomendatsii. Pervichnaia nadpochechnikovaia nedostatochnost', 2021 g. Available at https://cr.minzdrav.gov.ru/recomend/524_2/ Accessed: 23.05.2022 (in Russian).
30. Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124(18):3706-14. DOI:10.1002/cncr.31629
31. Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99:4078-85. DOI:10.1210/jc.2014-2306
32. Protsenko SA, Antimonik N Iu, Bershtein LM, et al. Prakticheskie rekomendatsii po upravleniiu immunooposredovannymi nezhelatel'nymi iavleniiami. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO #3s2. 2020;10:50 (in Russian). DOI:10.18027 / 2224-5057-2020-10-3s2-50
2. Bekema HJ, MacLennan S, Imamura M, et al. Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. Eur Urol. 2013;64(5):799-810. DOI:10.1016/j.eururo.2013.04.033
3. Darzy KH, Shalet SM. Hypopituitarism following radiotherapy. Pituitary. 2009;12(1):40-50. DOI:10.1007/s11102-008-0088-4
4. van Dorp W, van Beek RD, Laven JS, et al. Long-term endocrine side effects of childhood Hodgkin's lymphoma treatment: a review. Hum Reprod Update. 2012;18(1):12-28. DOI:10.1093/humupd/dmr038
5. Боброва Е.И., Фадеев В.В., Сотников В.М., и др. Морфофункциональные нарушения щитовидной железы после лучевой терапии опухолевых заболеваний. Клиническая и экспериментальная тиреоидология. 2014;10(3):45-52 [Bobrova EI, Fadeyev VV, Sotnikov VM, et al. Thyroid disorders after radiation therapy in childhood. Clinical and experimental thyroidology. 2014;10(3):45-52 (in Russian)]. DOI:10.14341/ket2014345-52
6. Рак молочной железы. ВОЗ. 2021. Режим доступа: https://www.who.int/ru/news-room/fact-sheets/detail/breast-cancer. Ссылка активна на 23.05.2022 [Mammary cancer. WHO. 2021. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/breast-cancer. Accessed: 23.05.2022 (in Russian)].
7. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):33. DOI:10.1186/s40659-017-0140-9
8. Cancer deaths by type, World, 2019. Total annual number of deaths from cancers across all ages and both sexes, broken down by cancer type. Our World in Data. Available at: https://ourworldindata.org/grapher/total-cancer-deaths-by-type?time=earliest. Accessed: 23.05.2022.
9. Tsang JYS, Tse GM. Molecular Classification of Breast Cancer. Adv Anat Pathol. 2020;27(1):27-35. DOI:10.1097/PAP.0000000000000232
10. Стенина М.Б., Жукова Л.Г., Королева И.А., и др. Практические рекомендации по лекарственному лечению рака молочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2020;10:09 [Stenina MB, Zhukova LG, Koroleva IA, et al. Prakticheskie rekomendatsii po lekarstvennomu lecheniiu raka molochnoi zhelezy. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO #3s2. 2020;10:09 (in Russian)]. DOI:10.18027 / 2224-5057-2019-9-3s2-128-163
11. Семиглазова Т.Ю., Семиглазов В.В., Клименко В.В., и др. Применение алпелисиба для лечения HR+ HER2-метастатического рака молочной железы у пациентов с мутацией PIK3CA: результаты исследования SOLAR-1. Фарматека. 2020;7:15-23 [Semiglazova TIu, Semiglazov VV, Klimenko VV, et al. Primenenie alpelisiba dlia lecheniia HR HER2-metastaticheskogo raka molochnoi zhelezy u patsientov s mutatsiei PIK3CA: rezul'taty issledovaniia SOLAR-1. Farmateka. 2020;7:15-23 (in Russian)]. DOI:10.18565/pharmateca.2020.7.15-23
12. Chen X, Wei L, Chi L, et al. Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database. Br J Clin Pharmacol. 2022;88(5):2180-9. DOI:10.1111/bcp.15143
13. Мазурина Н.В., Артамонова Е.В., Белоярцева М.Ф., и др. Консенсус по профилактике и коррекции гипергликемии у пациентов, получающих терапию препаратом алпелисиб. Современная Онкология. 2020;22(4):56-9 [Mazurina NV, Artamonova EV, Beloyartseva MF, et al. The consensus on the prevention and correction of hyperglyce-mia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib. Journal of Modern Oncology. 2020;22(4):56-9 (in Russian)]. DOI:10.26442/18151434.2020.4.200566
14. Inaba H, Ariyasu H, Okuhira H, et al. Endocrine dysfunctions during treatment of immune-checkpoint inhibitors. Trends Immunother. 2018;2(2):565. DOI:10.24294/ti.v2i2.606
15. Шубникова Е.В., Букатина Т.М., Вельц Н.Ю., и др. Ингибиторы контрольных точек иммунного ответа: новые риски нового класса противоопухолевых средств. Безопасность и риск фармакотерапии. 2020;8(1):9-22 [Shubnikova EV, Bukatina TM, Velts NYu, et al. Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents. Safety and Risk of Pharmacotherapy. 2020;8(1):9-22 (in Russian)]. DOI:10.30895/2312-7821-2020-8-1-9-22
16. Ferrari SM, Fallahi P, Galetta F, et al. Thyroid disorders induced by checkpoint inhibitors. Rev Endocr Metab Disord. 2018;19(4):325-33. DOI:10.1007/s11154-018-9463-2
17. Государственный реестр лекарственных средств. Режим доступа: https://grls.rosminzdrav.ru/grls.aspx. Ссылка активна на 22.05.2022 [Available at: https://grls.rosminzdrav.ru/grls.aspx. Accessed: 22.05.2022 (in Russian)].
18. Tjulandin S, Demidov L, Moiseyenko V, et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. Eur J Cancer. 2021;149:222-32. DOI:10.1016/j.ejca.2021.02.030
19. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173-82. DOI:10.1001/jamaoncol.2017.3064
20. Chang LS, Barroso-Sousa R, Tolaney SM, et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019;40(1):17-65. DOI:10.1210/er.2018-00006
21. Kurimoto C, Inaba H, Ariyasu H, et al. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer Sci. 2020;111(5):1468-77. DOI:10.1111/cas.14363
22. Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583-9. DOI:10.1093/annonc/mdw640
23. Yamauchi I, Yasoda A, Matsumoto S, et al. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS One. 2019;14(5):e0216954. DOI:10.1371/journal.pone.0216954
24. Higham CE, Olsson-Brown A, Carroll P, et al. SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect. 2018;7(7):G1-7. DOI:10.1530/EC-18-0068
25. Castinetti F, Borson-Chazot F. Immunotherapy-induced endocrinopathies: Insights from the 2018 French Endocrine Society Guidelines. Bull Cancer. 2019;106(5):492-6. DOI:10.1016/j.bulcan.2019.02.003
26. Трошина Е.А., Панфилова Е.А., Михина М.С., и др. Клинические рекомендации «Острые и хронические тиреоидиты (исключая аутоиммунный тиреоидит)». Проблемы эндокринологии. 2021;67(2):57-83 [Troshina EA, Panfilova EA, Mikhina MS, et al. Clinical practice guidelines for acute and chronic thyroiditis (excluding autoimmune thyroiditis). Problemy Endokrinologii. 2021;67(2):57-83 (in Russian)]. DOI:10.14341/probl12747
27. Garon-Czmil J, Petitpain N, Rouby F, et al. Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database. Sci Rep. 2019;9(1):19419. DOI:10.1038/s41598-019-56026-5
28. Gutenberg A, Larsen J, Lupi I, et al. A radiologic score to distinguish autoimmune hypophysitis from nonsecreting pituitary adenoma preoperatively. AJNR Am J Neuroradiol. 2009;30(9):1766-72. DOI:10.3174/ajnr.A1714
29. Клинические рекомендации. Первичная надпочечниковая недостаточность, 2021 г. Режим доступа: https://cr.minzdrav.gov.ru/recomend/524_2/ Ссылка активна на 23.05.2022 [Klinicheskie rekomendatsii. Pervichnaia nadpochechnikovaia nedostatochnost', 2021 g. Available at https://cr.minzdrav.gov.ru/recomend/524_2/ Accessed: 23.05.2022 (in Russian)].
30. Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124(18):3706-14. DOI:10.1002/cncr.31629
31. Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99:4078-85. DOI:10.1210/jc.2014-2306
32. Проценко С. А., Антимоник Н. Ю., Берштейн Л. М., и др. Практические рекомендации по управлению иммуноопосредованными нежелательными явлениями. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2020;10:50 [Protsenko SA, Antimonik N Iu, Bershtein LM, et al. Prakticheskie rekomendatsii po upravleniiu immunooposredovannymi nezhelatel'nymi iavleniiami. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO #3s2. 2020;10:50 (in Russian)].
DOI:10.18027 / 2224-5057-2020-10-3s2-50
________________________________________________
2. Bekema HJ, MacLennan S, Imamura M, et al. Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. Eur Urol. 2013;64(5):799-810. DOI:10.1016/j.eururo.2013.04.033
3. Darzy KH, Shalet SM. Hypopituitarism following radiotherapy. Pituitary. 2009;12(1):40-50. DOI:10.1007/s11102-008-0088-4
4. van Dorp W, van Beek RD, Laven JS, et al. Long-term endocrine side effects of childhood Hodgkin's lymphoma treatment: a review. Hum Reprod Update. 2012;18(1):12-28. DOI:10.1093/humupd/dmr038
5. Bobrova EI, Fadeyev VV, Sotnikov VM, et al. Thyroid disorders after radiation therapy in childhood. Clinical and experimental thyroidology. 2014;10(3):45-52 (in Russian). DOI:10.14341/ket2014345-52
6. Рак молочной железы. ВОЗ. 2021. Режим доступа: https://www.who.int/ru/news-room/fact-sheets/detail/breast-cancer. Ссылка активна на 23.05.2022 [Mammary cancer. WHO. 2021. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/breast-cancer. Accessed: 23.05.2022 (in Russian)].
7. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):33. DOI:10.1186/s40659-017-0140-9
8. Cancer deaths by type, World, 2019. Total annual number of deaths from cancers across all ages and both sexes, broken down by cancer type. Our World in Data. Available at: https://ourworldindata.org/grapher/total-cancer-deaths-by-type?time=earliest. Accessed: 23.05.2022.
9. Tsang JYS, Tse GM. Molecular Classification of Breast Cancer. Adv Anat Pathol. 2020;27(1):27-35. DOI:10.1097/PAP.0000000000000232
10. Stenina MB, Zhukova LG, Koroleva IA, et al. Prakticheskie rekomendatsii po lekarstvennomu lecheniiu raka molochnoi zhelezy. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO #3s2. 2020;10:09 (in Russian). DOI:10.18027 / 2224-5057-2019-9-3s2-128-163
11. Semiglazova TIu, Semiglazov VV, Klimenko VV, et al. Primenenie alpelisiba dlia lecheniia HR HER2-metastaticheskogo raka molochnoi zhelezy u patsientov s mutatsiei PIK3CA: rezul'taty issledovaniia SOLAR-1. Farmateka. 2020;7:15-23 (in Russian). DOI:10.18565/pharmateca.2020.7.15-23
12. Chen X, Wei L, Chi L, et al. Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database. Br J Clin Pharmacol. 2022;88(5):2180-9. DOI:10.1111/bcp.15143
13. Mazurina NV, Artamonova EV, Beloyartseva MF, et al. The consensus on the prevention and correction of hyperglyce-mia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib. Journal of Modern Oncology. 2020;22(4):56-9 (in Russian). DOI:10.26442/18151434.2020.4.200566
14. Inaba H, Ariyasu H, Okuhira H, et al. Endocrine dysfunctions during treatment of immune-checkpoint inhibitors. Trends Immunother. 2018;2(2):565. DOI:10.24294/ti.v2i2.606
15. Shubnikova EV, Bukatina TM, Velts NYu, et al. Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents. Safety and Risk of Pharmacotherapy. 2020;8(1):9-22 (in Russian). DOI:10.30895/2312-7821-2020-8-1-9-22
16. Ferrari SM, Fallahi P, Galetta F, et al. Thyroid disorders induced by checkpoint inhibitors. Rev Endocr Metab Disord. 2018;19(4):325-33. DOI:10.1007/s11154-018-9463-2
17. Available at: https://grls.rosminzdrav.ru/grls.aspx. Accessed: 22.05.2022 (in Russian).
18. Tjulandin S, Demidov L, Moiseyenko V, et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. Eur J Cancer. 2021;149:222-32. DOI:10.1016/j.ejca.2021.02.030
19. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173-82. DOI:10.1001/jamaoncol.2017.3064
20. Chang LS, Barroso-Sousa R, Tolaney SM, et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019;40(1):17-65. DOI:10.1210/er.2018-00006
21. Kurimoto C, Inaba H, Ariyasu H, et al. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer Sci. 2020;111(5):1468-77. DOI:10.1111/cas.14363
22. Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583-9. DOI:10.1093/annonc/mdw640
23. Yamauchi I, Yasoda A, Matsumoto S, et al. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS One. 2019;14(5):e0216954. DOI:10.1371/journal.pone.0216954
24. Higham CE, Olsson-Brown A, Carroll P, et al. SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect. 2018;7(7):G1-7. DOI:10.1530/EC-18-0068
25. Castinetti F, Borson-Chazot F. Immunotherapy-induced endocrinopathies: Insights from the 2018 French Endocrine Society Guidelines. Bull Cancer. 2019;106(5):492-6. DOI:10.1016/j.bulcan.2019.02.003
26. Troshina EA, Panfilova EA, Mikhina MS, et al. Clinical practice guidelines for acute and chronic thyroiditis (excluding autoimmune thyroiditis). Problemy Endokrinologii. 2021;67(2):57-83 (in Russian). DOI:10.14341/probl12747
27. Garon-Czmil J, Petitpain N, Rouby F, et al. Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database. Sci Rep. 2019;9(1):19419. DOI:10.1038/s41598-019-56026-5
28. Gutenberg A, Larsen J, Lupi I, et al. A radiologic score to distinguish autoimmune hypophysitis from nonsecreting pituitary adenoma preoperatively. AJNR Am J Neuroradiol. 2009;30(9):1766-72. DOI:10.3174/ajnr.A1714
29. Klinicheskie rekomendatsii. Pervichnaia nadpochechnikovaia nedostatochnost', 2021 g. Available at https://cr.minzdrav.gov.ru/recomend/524_2/ Accessed: 23.05.2022 (in Russian).
30. Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124(18):3706-14. DOI:10.1002/cncr.31629
31. Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99:4078-85. DOI:10.1210/jc.2014-2306
32. Protsenko SA, Antimonik N Iu, Bershtein LM, et al. Prakticheskie rekomendatsii po upravleniiu immunooposredovannymi nezhelatel'nymi iavleniiami. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO #3s2. 2020;10:50 (in Russian). DOI:10.18027 / 2224-5057-2020-10-3s2-50
Авторы
А.А. Глибка, Н.В. Мазурина, Е.А. Трошина*
ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия
*troshina@inbox.ru
Endocrinology Research Centre, Moscow, Russia
*troshina@inbox.ru
ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия
*troshina@inbox.ru
________________________________________________
Endocrinology Research Centre, Moscow, Russia
*troshina@inbox.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.